Updated Jul 16, 2026
Cloonan Michael is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market sales: $2.71M.
Michael Cloonan is a corporate executive known for his roles at Sionna Therapeutics, Inc. and bluebird bio, Inc. He has served as President and CEO, as well as a Director, contributing to the development of treatments for cystic fibrosis.
| Role | President & CEO, Director |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2025-10-15 | SION | Sionna Therapeutics, Inc. | S — Open-market sale | 200 | $34.00 | $7K |
| 2025-10-15 | SION | Sionna Therapeutics, Inc. | M — Option exercise | 200 | $6.11 | $1K |
| 2025-10-15 | SION | Sionna Therapeutics, Inc. | S — Open-market sale | 10.2K | $31.46 | $322K |
| 2025-10-15 | SION | Sionna Therapeutics, Inc. | M — Option exercise | 10.2K | $6.11 | $62K |
| 2025-10-15 | SION | Sionna Therapeutics, Inc. | S — Open-market sale | 14.8K | $31.11 | $460K |
| 2025-10-15 | SION | Sionna Therapeutics, Inc. | M — Option exercise | 14.8K | $6.11 | $90K |
| 2025-09-26 | SION | Sionna Therapeutics, Inc. | S — Open-market sale | 7.8K | $29.70 | $231K |
| 2025-09-26 | SION | Sionna Therapeutics, Inc. | M — Option exercise | 7.8K | $6.11 | $48K |
| 2025-09-26 | SION | Sionna Therapeutics, Inc. | S — Open-market sale | 17.2K | $28.85 | $496K |
| 2025-09-26 | SION | Sionna Therapeutics, Inc. | M — Option exercise | 17.2K | $6.11 | $105K |
| 2025-08-26 | SION | Sionna Therapeutics, Inc. | S — Open-market sale | 7.4K | $25.01 | $186K |
| 2025-08-26 | SION | Sionna Therapeutics, Inc. | M — Option exercise | 7.4K | $6.11 | $45K |
| 2025-08-26 | SION | Sionna Therapeutics, Inc. | S — Open-market sale | 17.6K | $24.96 | $439K |
| 2025-08-26 | SION | Sionna Therapeutics, Inc. | M — Option exercise | 17.6K | $6.11 | $107K |
| 2025-08-20 | SION | Sionna Therapeutics, Inc. | S — Open-market sale | 25.0K | $22.75 | $569K |
| 2025-08-20 | SION | Sionna Therapeutics, Inc. | M — Option exercise | 25.0K | $6.11 | $153K |
| 2025-06-02 | BLUE | bluebird bio, Inc. | D — Derivative transaction | 1.9K | — | |
| 2024-10-02 | BLUE | bluebird bio, Inc. | A — Grant or award | 37.4K | $0.00 |
Michael Cloonan is a corporate executive known for his roles at Sionna Therapeutics, Inc. and bluebird bio, Inc. He has served as President and CEO, as well as a Director, contributing to the development of treatments for cystic fibrosis.…
Recorded transactions: 0 open-market purchases () and 8 open-market sales ($2.71M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Cloonan Michael profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.